Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice.
Luís Gustavo Modelli de AndradeMariana Moraes ConttiHong Si NgaAriane Moyses BravinHenrique Mochida TakaseRosa Marlene VieroTrycia Nunes da SilvaKelem De Nardi ChagasLilian Monteiro Pereira PalmaPublished in: PloS one (2017)
The therapeutic use of eculizumab showed to be effective, with improvement of the microangiopathy parameters and persisting up to the end of the follow-up, without relapses. The additional risk of immunosuppression, leading to opportunistic infections, was well tolerated. The prophylactic use showed to be effective and safe; however, the doses and intervals should be individualized in order to avoid relapsed microangiopathy, especially in patients with factor H mutation.